AB Science SA

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

28 Oct 2024 11:47:33 By Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

17 Oct 2024 12:28:54 By Nasdaq GlobeNewswire

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

10 Oct 2024 01:28:04 By Nasdaq GlobeNewswire

AB Science announces a slight delay in the publication of its 2024 half-year financial report

30 Sep 2024 11:33:35 By Nasdaq GlobeNewswire

AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

26 Sep 2024 01:28:30 By Nasdaq GlobeNewswire

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

23 Sep 2024 10:51:06 By Nasdaq GlobeNewswire

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

08 Jul 2024 00:56:02 By Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

28 Jun 2024 05:31:02 By Nasdaq GlobeNewswire

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

31 May 2024 09:30:34 By Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

29 May 2024 11:02:52 By Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2023 and provides an update on its activities

15 May 2024 13:16:47 By Nasdaq GlobeNewswire

AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036

13 May 2024 11:08:35 By Nasdaq GlobeNewswire

AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient

07 May 2024 11:05:45 By Nasdaq GlobeNewswire

AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

02 May 2024 12:14:41 By Nasdaq GlobeNewswire

AB Science announces a slight delay in the publication of its 2023 annual financial report

30 Apr 2024 11:56:04 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS

03 Apr 2024 11:08:55 By Nasdaq GlobeNewswire

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

13 Mar 2024 06:58:59 By Nasdaq GlobeNewswire

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

07 Mar 2024 08:20:57 By Nasdaq GlobeNewswire

AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company

06 Mar 2024 13:21:09 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

01 Mar 2024 11:07:34 By Nasdaq GlobeNewswire